Design, synthesis, and evaluation of radiolabeled integrin α vβ3 receptor antagonists for tumor imaging and radiotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 4, 2003, Pages 627-641

  Harris, Thomas D ^a   Kalogeropoulos, Shirley ^a   Nguyen, Tiffany ^a   Liu, Shuang ^a   Bartis, Judit ^a   Ellars, Charles ^a   Edwards, Scott ^a   Onthank, David ^a   Silva, Paula ^a   Yalamanchili, Padmaja ^a   Robinson, Simon ^a   Lazewatsky, Joel ^a   Barrett, John ^a   Bozarth, Jeffrey ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiogenesis; Radionuclide therapy; Tumor imaging; v 3 antagonists

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3 [[[1 [3 (1H IMIDAZOL 2 YLAMINO)PROPYL] 1H INDAZOL 5 YL]CARBONYL]AMINO] N (MESITYLSULFONYL)ALANINE; ALPHA5 INTEGRIN; BETA3 INTEGRIN; DOXORUBICIN; IMIDAZOLE DERIVATIVE; INDIUM 111; QUINOLONE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SHO 66; TA 120; TA 120 IN 111; TA 138; TA 138 Y 89; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR ANTAGONIST; YTTRIUM; YTTRIUM 90;

ANGIOGENESIS; ANIMAL MODEL; BREAST ADENOCARCINOMA; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CELL ADHESION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOCHEMISTRY; RECEPTOR BINDING; TISSUE DISTRIBUTION;

EID: 12444264852     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322287727     Document Type: Conference Paper

References (24)

1. 3 on vascular cells during wound repair. Am J Pathol 1996;148:1407.
2. 3 Expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997;71:320.
3. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157.
4. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815.
5. Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A, Jr, Slee AM. Novel small molecule av integrin antagonists: Comparative anticancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999;19:959.
6. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug to tumor vasculature in a mouse model. Science 1998;279:377.
7. Mizejewski GJ. Role of integrins in cancer: Survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124.
8. 3 expression by bone-residing breast cancer metastases. Diag Mol Pathol 1996;5:127.
9. 3. Anti-cancer Res 1999;19:1529.
10. 3 is modulated by a focal adhesion kinase pathway. Cancer Res 1999;59:1655.
11. Haubner R, Wester H-J, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nuc Med 2001;42:326.
12. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Can Res 2001;61:1781.
13. van Hagen PM, Breeman WAP, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, Krenning EP, de Jong M. Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int J Cancer 2000;8:186.
14. 3. J Nuc Med 2000;41:259P.
15. 3. J Med Chem 2000;43:41.
16. Wityak J, Bristol-Meyers Squibb, personal communication.
17. vβ3 antagonists as potential tumor imaging agents. J Labeled Cpd Radiopharm 2001;44:Suppl. 1,S60.
18. 3. J Med Chem 2000;43:27.
19. v integrin antagonists: Novel anticancer agents. Exp Opin Invest Drugs 2000;9:1271.
20. 3. Exp Opin Ther Patents 2000;10: 1367.
21. 3 (the vitronectin receptor). Drug Disc Today 2000;5:397.
22. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 1998;25:201.
23. Yalamanchili P, Bristol-Meyers Squibb Medical Imaging, unpublished results.
24. Perez CA, Brady LW. In Principles and Practice of Radiation Oncology. Perez CA and Brady LW, Eds, 2nd ed. J.B. Lippincott Co, Philadelphia, 1992, p 6.